Similarly, the allosteric inhibitor used in this study, SP-2509, has been shown to disrupt the LSD1-ZNF217 interaction and has proven highly effective in inhibiting the proliferation of prostate cancer cells, much more so than ‘catalytic’ inhibitors. Here, ZNF217 is linked to prostate cancer.